ArticleParasites & vectors2026
Efficacy of Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) against circulating microfilariae in dogs infected with Dirofilaria immitis.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine heartworm disease remains a global threat despite the availability of multiple preventive options, a challenge compounded by the emergence of macrocyclic lactone-resistant heartworm strains, especially in the USA. Circulating microfilariae play a pivotal role in heartworm transmission, serving as a continuous infection reservoir for mosquito vectors. Therefore, targeting this life cycle stage is critical in the framework of a comprehensive and multimodal heartworm prevention strategy.
methodsA randomised, blinded, negative-controlled laboratory study evaluated the efficacy of Simparica Trio® (Zoetis Inc., Parsippany, NJ, USA), containing a minimum dosage of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel, against circulating microfilariae. Dogs naturally infected with heartworm and harbouring circulating microfilariae were enrolled in the study. Twelve dogs received a single treatment with Simparica Trio as per recommended label dosage, and efficacy was compared with an untreated control group of 10 dogs weekly for 28 days.
resultsThere were no adverse events recorded in this study. Following a single oral dose of Simparica Trio, a significant reduction in microfilaria counts in the Simparica Trio-treated group relative to the control group was first detected within 7 days (P < 0.0001), resulting in an efficacy of 99.9% (98.9%) based on geometric (arithmetic) means. The efficacy remained at least 99.9% (≥ 99.5%) based on geometric (arithmetic) means for 28 days (P < 0.0001).
conclusionsA single oral dose of Simparica Trio was highly effective against circulating microfilariae in naturally infected dogs with D. immitis for 1 month. Combining its effects on migrating L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.